In vitro and in vivo experimental models for drug screening and development for Chagas disease Alvaro José Romanha; Solange Lisboa de Castro; Maria de Nazaré Correia Soeiro; Joseli Lannes-Vieira; Isabela Ribeiro; André Talvani; Bernadette Bourdin; Bethania Blum; Bianca Olivieri; Carlos Zani; Carmenza Spadafora; Egler Chiari; Eric Chatelain; Gabriela Chaves; José Eduardo Calzada; Juan Manuel Bustamante; Lucio H Freitas-Junior; Luz I Romero; Maria Terezinha Bahia; Michel Lotrowska; Milena Soares; Sonia Gumes Andrade, Tanya Armstrong; Wim Degrave; Zilton de Araújo Andrade PAGE: 233-238 | DOI: 10.1590/S0074-02762010000200022

The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease J Antonio Marin-Neto ; Anis Rassi Jr; Alvaro Avezum Jr; Antonio C Mattos; Anis Rassi PAGE: 319-324 | DOI: 10.1590/S0074-02762009000900042

Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects María Montalto de Mecca; Laura C Bartel; Carmen Rodríguez de Castro; José A Castro PAGE: 549-553 | DOI: S0074-02762008000600007

Benznidazole levels in blood vary with age in rats Romina Fernanda Bulffer; José Alberto Castro; Silvia Laura Fanelli PAGE: 374-377 | DOI: 10.1590/S0074-02762011000300021

Trypanosoma cruzi: parasite antigens sequestered in heart interstitial dendritic cells are related to persisting myocarditis in benznidazole-treated mice Renata Siqueira Portella; Sonia G Andrade PAGE: 1023-1030 | DOI: 10.1590/S0074-02762009000700015

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras Josep M Escribà; Elisa Ponce; Alberto de Dios Romero; Pedro Albajar Viñas; Andrea Marchiol; Glòria Bassets; Pedro Pablo Palma; M Angeles Lima; Concepción Zúniga; Carlos Ponce PAGE: 986-991 | DOI: 10.1590/S0074-02762009000700008

Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment Marta de Lana; Leonardo A Lopes; Helen R Martins; Maria T Bahia; Girley F Machado-de-Assis; Ana P Wendling; Olindo A Martins-Filho; Roberto A Montoya; João CP Dias; Pedro Albajar-Viñas; José R Coura PAGE: 1139-1147 | DOI: 10.1590/S0074-02762009000800011

A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention Girley Francisco Machado-de-Assis, Glaucia Alessio Diniz, Roberto Araújo Montoya, João Carlos Pinto Dias, José Rodrigues Coura, George Luiz Lins Machado-Coelho, Pedro Albajar-Viñas, Rosália Morais Torres, Marta de Lana PAGE: 873-880 | DOI: 10.1590/0074-0276130122

Benznidazole-induced genotoxicity in diploid cells of Aspergillus nidulans Edilson N Kaneshima, Marialba A Alves de Castro-Prado* PAGE: 325-330

Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components? Maria Jose Morilla, Maria Jimena Prieto, Eder Lilia Romero PAGE: 213-219

Variation in Susceptibility to Benznidazole in Isolates Derived from Trypanosoma cruzi Parental Strains VM Veloso, CM Carneiro, MJO Toledo, M Lana, E Chiari, WL Tafuri,MT Bahia PAGE: 1005-1011

Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease María Cecilia Albareda, Susana Adriana Laucella PAGE: 414-421 | DOI: 10.1590/0074-02760140386

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole Marisa Liliana Fernández, Maria Elena Marson, Juan Carlos Ramirez, Guido Mastrantonio, Alejandro Gabriel Schijman, Jaime Altcheh, Adelina Rosa Riarte, Facundo García Bournissen DOI: 10.1590/0074-02760150401

Up-regulation of ATP-binding cassette transporters in the THP-1 human macrophage cell line by the antichagasic benznidazole Virginia G Perdomo, Juan P Rigalli, Marcelo G Luquita, José M Pellegrino, María Laura Ruiz, Viviana A Catania PAGE: 707-711 | DOI: 10.1590/0074-02760160080

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial Anis Rassi Jr, José Antonio Marin-Neto, Anis Rassi PAGE: 224-235 | DOI: 10.1590/0074-02760160334

Overexpression of eukaryotic initiation factor 5A (eIF5A) affects susceptibility to benznidazole in Trypanosoma cruzi populations Douglas de Souza Moreira, Ana Paula Duarte, Fabiano Sviatopolk Mirsky Pais, Rosiane Aparecida da Silva-Pereira, Alvaro José Romanha, Sergio Schenkman, Silvane Maria Fonseca Murta DOI: 10.1590/0074-02760180162

Critical analysis of Chagas disease treatment in different countries Fernanda de Souza Nogueira Sardinha Mendes, Jose Antonio Perez-Molina, Andrea Angheben, Sheba K Meymandi, Sergio Sosa-Estani, Israel Molina DOI: 10.1590/0074-02760210034

Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach* Joseli Lannes-Vieira DOI: 10.1590/0074-02760220019

Anxiety, depression, and memory loss in Chagas disease: a puzzle far beyond neuroinflammation to be unpicked and solved* Joseli Lannes-Vieira, Glaucia Vilar-Pereira, Leda Castaño Barrios, Andrea Alice Silva DOI: 10.1590/0074-02760220287

Benznidazole treatment decreases IL-6 levels in Trypanosoma cruzi-infected human adipocytes differentiated from adipose tissue-derived stem cells Leyllane Rafael Moreira, Ana Carla Silva, Cíntia Nascimento da Costa Oliveira, Claudeir Dias da Silva Júnior, Amanda Vasconcelos Nascimento, Kamila Kássia dos Santos Oliveira, Ana Karine de Araújo Soares, Karina Lidianne Alcântara Saraiva, Milena de Paiva Cavalcanti, Virginia Maria Barros de Lorena DOI: 10.1590/0074-02760220295